Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19

Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19

The study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of COVID-19 pneumonia.

There is no vaccine or antiviral treatment for human coronavirus, so this study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of COVID-19 pneumonia.

Inclusion Criteria:

• The participants were diagnosed as COVID-19 pneumonia, according to the notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 4 or update version) made by National Health Commission of the People's Republic of China;
• Participants aged over 18;
• Written the informed consent.

Exclusion Criteria:

• Hypersensitivity to chloroquine or hydroxychloroquine;
• Women during pregnancy;
• Severe heart, lung, kidney, brain, blood diseases or other important systemic diseases;
• Participants with retinal disease, hearing loss;
• Participants with severe neurological and mental illness;
• Subjects were considered to be unable to complete the study, or not suitable for the study by researchers.

Exit criteria:

• Subjects asked to withdraw the study
• Subject will benefit if withdraw according to researchers' suggestions